Technical Analysis for SVRA - Savara, Inc.
|Grade||Last Price||% Change||Price Change|
SVRA closed up 6.2 percent on Thursday, January 18, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical SVRA trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Lower Bollinger Band Walk||Weakness||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Lower Bollinger Band Touch||Weakness||0.00%|
|Jan 18||Oversold Stochastic||Weakness||0.00%|
|Jan 17||Hammer Candlestick||Bullish||6.20%|
|Jan 17||Lower Bollinger Band Walk||Weakness||6.20%|
|Jan 17||Wide Bands||Range Expansion||6.20%|
|Jan 17||Lower Bollinger Band Touch||Weakness||6.20%|
|Jan 17||Oversold Stochastic||Weakness||6.20%|
|Jan 16||Fell Below 50 DMA||Bearish||3.85%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SVRA news...
|52 Week High||17.19|
|52 Week Low||4.6|
|200-Day Moving Average||8.6077|
|50-Day Moving Average||13.1518|
|20-Day Moving Average||14.456|
|10-Day Moving Average||13.359|
|Average True Range||0.8227|
|Chandelier Exit (Long, 3 ATRs )||14.7219|
|Chandelier Exit (Short, 3 ATRs )||13.8181|
|Upper Bollinger Band||17.2304|
|Lower Bollinger Band||11.6816|
|Percent B (%b)||0.18|
|MACD Signal Line||0.0951|
|Market Cap||306.9 Million|
|Num Shares||24.2 Million|
|Price-to-Earnings (P/E) Ratio||-3.62|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||14.40|
|Resistance 3 (R3)||14.25||13.53||14.11|
|Resistance 2 (R2)||13.53||13.09||13.60||14.02|
|Resistance 1 (R1)||13.10||12.82||13.32||13.25||13.92|
|Support 1 (S1)||11.96||11.94||12.17||12.11||11.44|
|Support 2 (S2)||11.24||11.67||11.31||11.34|
|Support 3 (S3)||10.81||11.24||11.25|
|Support 4 (S4)||10.96|